Long-term outcome of endocrine function in patients with neurohypophyseal germinomas.
Since neurohypophyseal germinomas occur at the pituitary and hypothalamic axis in children and adolescents, the endocrinopathy is one of the common and critical QOL determinants. We carried out a retrospective study on the outcome of endocrine function in patients with neurohypophyseal germinoma, in order to improve or preserve pituitary function after treatment. Sixteen patients (7 men and 9 women), aged 6 to 26 years were admitted and followed up for 95.3 (14-197) months. DI was noted in 12 patients in pretreatment and 16 in posttreatment regardless of tumor size. We carried out the replacement of GH in all 8 patients, presenting the symptoms under 15 years of age. Gonadal or gonadotropic, thyroid and adrenal hormones were replaced in 9, 12 and 15 patients, respectively. Patients with large tumor compressing chiasm or hypothalamus needed hormonal replacement such as gonadal or gonadotropic and thyroid hormones more frequently (<0.01) than those with small one. In addition, two patients with a small tumor at the pituitary stalk and the 3rd ventricle floor showed the improvement of secretion pattern in gonadotropins and ACTH after chemotherapy, although they later needed radiation therapy to control the tumor. Based on our study and review of literature, the endocrinological studies before and after treatment demonstrated that pituitary dysfunction present before treatment persisted or worsened even after tumor remission, except for patients with small and localized ones. The poor endocrine results is considered to be largely radiation-related. Chemotherapy alone seems to be insufficient to obtain complete response (CR). To avoid radiation related pituitary injury, combination of 24 Gy or less dosage of radiation and appropriate chemotherapy is essential. The earlier diagnosis by repeatedly using neuroimaging and serum and CSF tumor markers and earlier initiation of treatment, before irreversible pituitary-hypothalamic damage occurs, contributes to improvement of the outcome of pituitary functions in patients with neurohypophyseal germinomas.
Sa ki
N
N
Department of Neurological Surgery, Chiba University School of Medicine, Japan.
Tamaki
K
K
Murai
H
H
Kubota
M
M
Yamaura
A
A
Uchida
D
D
Noguchi
Y
Y
Nakamura
S
S
Tatsuno
I
I
Wada
K
K
Minagawa
M
M
Yasuda
T
T
D000293:Adolescent; D000328:Adult; D000970:Antineoplastic Agents / Q000627:therapeutic use; D002648:Child; D002945:Cisplatin / Q000627:therapeutic use; D003131:Combined Modality Therapy; D004702:Endocrine Glands / Q000503:physiopathology*; D005260:Female; D018237:Germinoma / Q000473:pathology / Q000503:physiopathology* / Q000532:radiotherapy / Q000601:surgery; D007987:Gonadotropin-Releasing Hormone; D013006:Growth Hormone / Q000627:therapeutic use; D006728:Hormones / Q000627:therapeutic use; D006801:Humans; D007328:Insulin; D008297:Male; D010903:Pituitary Gland, Anterior; D010904:Pituitary Gland, Posterior; D010911:Pituitary Neoplasms / Q000473:pathology / Q000503:physiopathology* / Q000532:radiotherapy / Q000601:surgery; D012189:Retrospective Studies; D013973:Thyrotropin-Releasing Hormone
D000970:Antineoplastic Agents; D006728:Hormones; D007328:Insulin; D007987:Gonadotropin-Releasing Hormone; D013973:Thyrotropin-Releasing Hormone; D013006:Growth Hormone; D002945:Cisplatin